|Slideshows|October 4, 2018

GI Case Quiz: RUQ Pain, Fevers, & Jaundice

RUQ pain x3 days, fevers x24h. LFTs are elevated. Which of these tests should you order?

Newsletter

Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.

Subscribe Now!

Related Content

FDA Approves Simplified Once-Monthly Mirikizumab-mrkz Regimen for Ulcerative Colitis Maintenance Therapy

BySydney Jennings

November 5th 2025

GLP-1 Receptor Agonist GI Safety Comparable Within the Class, But Exceeds SGLT-2 Inhibitor Risk

ByGrace Halsey

November 4th 2025

Non-Celiac Gluten/Wheat Sensitivity Affects 1 in 10 Globally, Often with Comorbid IBS

ByGrace Halsey

October 30th 2025

FDA Approves Updated Indication Statement for Upadacitinib in Inflammatory Bowel Disease Treatment

BySydney Jennings

October 14th 2025

FDA OKs Subcutaneous Guselkumab Regimen for Ulcerative Colitis: Daily Dose

BySydney Jennings

October 14th 2025

GI Case Quiz: RUQ Pain, Fevers, & Jaundice

Newsletter

Related Content

FDA Approves Simplified Once-Monthly Mirikizumab-mrkz Regimen for Ulcerative Colitis Maintenance Therapy

GLP-1 Receptor Agonist GI Safety Comparable Within the Class, But Exceeds SGLT-2 Inhibitor Risk

Non-Celiac Gluten/Wheat Sensitivity Affects 1 in 10 Globally, Often with Comorbid IBS

FDA Approves Updated Indication Statement for Upadacitinib in Inflammatory Bowel Disease Treatment

FDA OKs Subcutaneous Guselkumab Regimen for Ulcerative Colitis: Daily Dose

Trending on Patient Care Online

This Year in Primary Care: 10 Critical Updates in 2025

Advancing Early Detection and Equitable Access in Alzheimer Disease Care

FDA Approves First Oral GLP-1 Receptor Agonist for Chronic Weight Management